TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05518695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2022
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2022
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2022
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2022
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
Study: NCT05020145

Intervention type: BIOLOGICAL
Intervention: BNT162b2 (Tozinameran)
Description: Covid-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: BNT162b2 (Tozinameran)
Description: Covid-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: BNT162b2 (Tozinameran)
Description: Covid-19 Vaccine
Study: NCT05215691

Intervention type: PROCEDURE
Intervention: Group I: TAPA block
Description: Postoperative analgesia will be provided with peripheral nerve block (TAPA)

Intervention type: PROCEDURE
Intervention: Group II: IV Morphine
Description: Postoperative analgesia will be provided with opioids
Study: NCT04709458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-2400
Description: Hematopoietic stem cells transplantation
Study: NCT06273618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
Study: NCT05399901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Description: Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-mode US biofeedback
Description: Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
Study: NCT04977570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1805 tablets
Description: Oral tablets of SYHA1805 with three pre-designed doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of placebo with matching doses
Study: NCT05758805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-invasive esophagoscopy
Description: mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP-SD AF ablation by a CF sensing catheter
Description: AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
Study: NCT06347393

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mammography and Breast Ultrasound
Description: Patients will be scanned using mammography and Breast Ultrasound for Breast Cancer Screening
Study: NCT05238831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Description: Given phesgo SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given subcutaneously (SC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT05204069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillation of cyclopentolate
Description: Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instillation of cyclopentolate
Description: Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
Study: NCT04051918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Piano Training
Description: Cognitive training via music learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Training
Description: Cognitive training via music learning
Study: NCT05911178

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: PET tracer binding to SV2A protein, used to study synaptic vesicle density.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: PET tracer binding to SV2A protein, used to study synaptic vesicle density.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: PET tracer binding to SV2A protein, used to study synaptic vesicle density.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714
Description: PET tracer binding to TSPO protein, used to study microglial activation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714
Description: PET tracer binding to TSPO protein, used to study microglial activation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714
Description: PET tracer binding to TSPO protein, used to study microglial activation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-RO-948
Description: PET tracer binding to tau protein, used to study the topography of tau deposition.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-RO-948
Description: PET tracer binding to tau protein, used to study the topography of tau deposition.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-RO-948
Description: PET tracer binding to tau protein, used to study the topography of tau deposition.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-PiB
Description: PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
Study: NCT01028872

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Study: NCT06199895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Polymeric Micelles for Injection
Description: 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Study: NCT04593823

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix Infusor
Description: Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Study: NCT05075512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib, fulvestrant
Description: anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
Study: NCT04773925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness counseling
Description: Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
Study: NCT06456489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solumedrol
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days
Study: NCT06410417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shorten abstinence time
Description: In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
Study: NCT06494618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shockwave Therapy
Description: 1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
Study: NCT05418959

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DermTech PLA noninvasive adhesive biopsy
Description: The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
Study: NCT06465628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: The participants should perform self-administered acupressure 12 weeks after training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral health education
Description: The participants should perform general oral care by themselves after the oral health education relating to xerostomia
Study: NCT04755738

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib plus microwave ablation
Description: Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Almonertinib plus microwave ablation
Description: Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
Study: NCT05420142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
Study: NCT05319262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pink noise exposure
Description: Continuous pink noise sound exposure at 45 dBA, throughout the whole night

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pink noise exposure
Description: Continuous pink noise sound exposure at 45 dBA, throughout the whole night

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Traffic noise
Description: 120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Traffic noise
Description: 120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
Study: NCT05701904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local mechanical vibration
Description: Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotblocker group
Description: It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
Study: NCT05502822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High definition transcranial alternating current stimulation
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high definition transcranial alternating current stimulation
Description: . In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
Study: NCT06411509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TC plus active rTMS
Description: The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tai Chi plus sham rTMS
Description: Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TC-alone
Description: Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity physical exercise
Description: To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
Study: NCT05773911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4% chitosan gel (pH 3.48).
Description: Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Chitosan brush
Description: Reciprocal Chitosan brush
Study: NCT05838690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Intubation Safety (PINS) Bundle
Description: The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan